ABPI Logo
  • Developing medicines
    • Responding to COVID-19
    • Clinical trials and research
    • Building a thriving environment for medicine discovery
    • UK-EU Future Relationship
    • Life Sciences Industrial Strategy
    • ABPI Medical Representatives Exam
  • Accessing medicines
    • How medicines are priced in the UK
    • Working with the NHS
    • Supply chain
    • Antimicrobial resistance (AMR)
    • Vaccines
    • What is the NICE Methods Review?
    • Rare diseases: Facing three challenges
  • Our ethics
    • ABPI Code of Practice
    • Disclosure UK
    • Appropriate prescribing
    • Patient & public involvement
  • Member representation
    • Events
    • Full membership
    • Working with our members​
    • ABPI Members List
    • Membership benefits
  • Who We Are
  • Media
  • Publications
  • Facts and Figures
  • Contact Us
MY ABPI LOGIN
 
  • The Association of the British Pharmaceutical Industry
  • Developing medicines
  • Academic collaboration, education & skills
  • Examples of industry-academic interactions

Examples of industry-academic interactions

These examples showcase the variety of projects that have arisen over the last two years, from more traditional partnerships between one company and one institution, to pioneering consortia and novel patient biobanks.

While there are over 1,000 links between the pharmaceutical industry and the academic sector in terms of placements and studentships for the individual, there are a number of longer-term, open collaborative projects between companies and institutions. These partnerships allow the exchange of knowledge and expertise, catalysing innovative, leading research in the UK.

Some collaborations have been running for a significant length of time, such as the Division of Signal Transduction Therapy (DSTT) at the University of Dundee which was created in 1998, and has secured renewed funding until 2020. There have been many collaborative projects that have formed in the last two years, and it is encouraging to see that many of the collaborations highlighted in the 2015 survey report are still being supported, such as the Alzheimer’s Research UK Dementia Consortium, which has since welcomed MSD as another collaborator.

Driven by the growing prominence of and need for personalised medicine, the Future Targeted Healthcare Manufacturing Hub endeavours to address the infrastructure and manufacturing challenges surrounding the development of new, targeted biological therapeutics. Led by UCL, the Hub is formed of several universities, governmental associations and over 30 pharmaceutical companies who share the common goal of bringing targeted healthcare into common usage through the development of novel manufacturing, formulation and control technologies.

Industry – Francis Crick Institute collaborations

The Francis Crick Institute continues to engage and collaborate with the pharmaceutical industry since its formation in 2015. Building on the original open science collaboration formed between the Crick and GSK in 2015, GSK have contributed significantly towards the development of the Biomedical Imaging lab at the Crick, which adds to the already vast level of facilities available at the institute.

Additionally, a five-year open science agreement between AstraZeneca and the Crick, announced in 2017, enables collaboration on early-stage research which could translate into novel insights and treatments across a range of disease areas, including cancers, cardiovascular and respiratory diseases. Funds from AstraZeneca, Cancer Research UK and the MRC will allow further innovation and knowledge exchange between these partners, maximising the impact of the scientific advances generated from the initiative.

NURTuRE

Arising from a recommendation in the UK renal research strategy report in 2016, NURTuRE brings together the universities of Bristol and Nottingham, medical research charity, Kidney Research UK, NHS trusts and the pharmaceutical companies AbbVie Inc, Evotec AV, Retrophin and UCB Celltech Biopharma with the aim of creating a national Kidney Biobank for chronic kidney disease (CKD) and nephrotic syndrome (NS).

A broad range of biological samples and data from almost 4,000 patients will be available to collaborators, other investigators and pharmaceutical companies, helping to facilitate the identification of new  biomarkers of CKD to help patients who will benefit from better, earlier diagnosis and develop person-specific new treatments, increase knowledge and understanding of NS and ultimately to provide better health outcomes for patients.

Antibody-Assisted Structure-Based Drug Discovery Consortium

Combining expertise in small molecular drug design, the Antibody-Assisted Structure-Based Drug Discovery Consortium links together the University of Leicester, UCB and LifeArc through the application of antibodies as tools to identify and characterise novel regulatory sites on therapeutically relevant target proteins. Ultimately, the consortium aims to guide the discovery and design of new small molecular therapeutics, in turn delivering significant benefits to the clinic.

Pfizer – University of Swansea Innovation Hub

Bringing together Pfizer and the University of Swansea, this project aims to set up an Innovation Hub based at the university’s School of Management, catalysing the exchange of skills and expertise with the aim of tackling healthcare challenges across Wales. By helping to develop a health system that links together the NHS, industry and academia, the Innovation Hub will work to bring great benefits to patients in Wales. The first phase of the partnership sees the recruitment of both a Professor of Enhanced Health Innovation, Engagement and Outcomes, and a Digital Technical Consultant, which will drive the project forward into the future.

Apollo Therapeutics Fund

A unique collaboration between AstraZeneca, GSK, Johnson & Johnson Innovation and Imperial College London, UCL and the University of Cambridge, Apollo Therapeutics constitutes a £40 million fund to support the translation of biomedical projects within partner universities into innovative new medicines licensed by industrial partners. Launched in 2016, the venture will run for six to eight years and fund approximately 20 projects with great therapeutic potential, and with expertise in drug discovery, Apollo Therapeutics provides a world-class environment for project growth.

Academic collaboration, education & skills

  • Careers in the pharmaceutical industry
  • ABPI Medical Representatives Exam
  • Links between industry and academia
  • Examples of industry-academic interactions
  • ABPI LINC

ABPI

The Association of the British Pharmaceutical Industry is a company limited by guarantee registered in England and Wales 
(registered number 09826787) and its registered office is at 7th Floor Southside,105 Victoria Street, London, SW1E 6QT.
Telephone +44 (0) 207 9303477

© ABPI 2021
  • Twitter Logo
  • LinkedIn
  • YouTube Logo

Devolved Nations

  • Cymru Wales
  • Northern Ireland
  • Scotland

Quick Links

  • ABPI Exam
  • Disclosure UK
  • Frequently Asked Questions
  • Careers
  • Schools
  • Acronym buster

Website Info

  • Terms and conditions
  • Accessibility
  • Cookie Policy

Prescription Medicines Code of Practice Authority (PMCPA)

The Prescription Medicines Code of Practice Authority (PMCPA) was established by The Association of the British Pharmaceutical Industry to operate the ABPI Code of Practice for the Pharmaceutical Industry independently of the ABPI. The PMCPA is a division of ABPI which is a company registered in England and Wales (registered number 09826787) with its registered office at 7th Floor, Southside, 105 Victoria Street, London SW1E 6QT.

Office of Health Economics (OHE)

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 7th Floor Southside, 105 Victoria Street, London, SW1E 6QT. OHE provides independent research, advisory and consultancy services on policy implications and economic issues within the pharmaceutical, health care and biotechnology sectors.